Table 3.

Active or planned clinical trials addressing important questions of ICI use in advanced EGFRm NSCLC.

Trial	Phase		Population	n	Intervention	Primary End Point(s)	Status
Question: Activity of second-line dual ICI therapy
ILLUMINATE/NCT03994393	2	EGFRm NSCLC that failed third generation TKI		100	Durvalumab + Tremelimumab + Platinum-Pemetrexed	OTRR*	Recruiting
CheckMate722/NCT02864251	3	EGFRm NSCLC that failed first- or second-line EGFR TKI therapy		365	(Arm B) Nivolumab + Ipilimumab vs (Arm C) Platinum-doublet	PFS	Active
Question: Activity of second-line combination ICI + chemotherapy
NCT03924050	3	Advanced EGFRm NSCLC that has progressed on EGFR TKI		350	Toripalimab + standard chemotherapy	PFS	Recruiting
CheckMate722/NCT02864251	3	EGFRm NSCLC that failed first- or second-line EGFR TKI therapy		365	(Arm A) Nivolumab + Platinum-doublet vs (Arm C) Platinum-doublet	PFS	Active
KEYNOTE-789/NCT03515837	3	EGFRm NSCLC resistant to EGFR TKI		492	Pembrolizumab + Pemetrexed + Chemotherapy vs Placebo + Pemetrexed + Chemotherapy	PFS, OS	Active
Question: Activity of second-line ICI + chemotherapy + antiangiogenic therapy
NCT04517526	2	Stage IV EGFRm NSCLC that has progressed on EGFR-TKI		60	Pemetrexed + Cisplatin/Carboplatin + Bevacizumab + Durvalumab + SBRT	PFS, OS	Not yet recruiting
Question: Activity of CD73/adenosine axis inhibition + ICI therapy in EGFRm NSCLC
No active studies*
Question: Activity of TNF-α agents + ICI therapy in EGFRm NSCLC
No active studies

Trial information obtained from ClinicalTrials.gov *A phase 1b/2 trial of oleclumab (CD73-ab) + osimertinib versus AZD4635 is currently recruiting (NCT03381274). This study does not have an ICI arm, but will provide helpful information on the utility and tolerability of oleclumab in EGFR NSCLC patients. OTRR, overall treatment response rate; PFS, progression-free survival; OS, overall survival; SBRT, stereotactic body radiation therapy.